Document is current

Article History

Accepted: 19 September 2024

First Online: 28 October 2024

Declarations

:

: The publication of this article was supported by Shionogi, Spain.

: CH-T has conducted consulting work for Shionogi, Angellini, Advanz, ViiV, Gilead Sciences, Janssen, and Merck Sharp & Dohme. CH-T has received research grants from Gilead Sciences and ViiV, as well as financial compensation for presentations from Shionogi, Gilead Sciences, Janssen, Merck Sharp & Dohme, and ViiV Healthcare. LM-M has been a consultant for MSD, Shionogi and Advanz, has served as a speaker for MSD, Pfizer and Shionogi and has received research grants from Pfizer, MSD and Shionogi. MR-A has conducted consulting work for Shionogi and Viatris. MR-A has served as a speaker for Pfizer, Gilead Sciences and Shionogi. AO has received research grants and speakers fees from Shionogi, Pfizer and MSD. GB has been a consultant for Pfizer, Astellas, Roche, MSD, Shionogi and Advanz, has served as a speaker for MSD, Pfizer, Roche, Advanz and Shionogi and has received research grants from Pfizer, Advanz and MSD. MSL has received remuneration for lectures and advisory boards (Advanz Pharma, Angelini Pharma, Janssen, Menarini, MSD, Pfizer, Shionogi, Viatris) and educational grants (Gilead, Tedec-Meiji).

: All authors have contributed to the conception of the work. All authors wrote the original draft and performed substantial contributions to the final manuscript. All authors reviewed and approved the final manuscript for submission. All authors agreed to be accountable for all aspects of the work.

: Not applicable for this review.